Mycapssa
Acromegaly, Flushing, Gastroenteritis + 4 more
Treatment
6 FDA approvals
17 Active Studies for Mycapssa
Treatment for
Acromegaly
What is Mycapssa
Octreotide
The Generic name of this drug
Treatment Summary
Acromegaly is a rare disorder caused by too much growth hormone in the body, leading to abnormal growth of the feet, hands, and face. It also causes organ enlargement and difficulty using insulin. Octreotide is a drug that works like somatostatin, a natural hormone, to reduce growth hormone levels. It has been used to treat acromegaly and other tumors in the past, but now there is a new delayed-release oral medication called Mycapssa that has been approved by the FDA to treat this condition.
Octreotide Acetate
is the brand name
Mycapssa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Octreotide Acetate
Octreotide
1988
89
Approved as Treatment by the FDA
Octreotide, otherwise known as Octreotide Acetate, is approved by the FDA for 6 uses such as metastatic Carcinoid Tumors and Gastroenteritis .
metastatic Carcinoid Tumors
Gastroenteritis
Diarrhea
Carcinoid Tumor
Acromegaly
Helps manage Acromegaly
Flushing
Effectiveness
How Mycapssa Affects Patients
Octreotide works like the hormone somatostatin and helps reduce growth hormones and the effects of too much insulin in the body. It also helps with flushing and diarrhea caused by tumors by reducing blood flow in the digestive system and decreasing hormones that lead to diarrhea. Taking octreotide may reduce gallbladder contractility, bile secretion, and the release of TSH, so it is important to monitor vitamin B12 levels in patients taking octreotide.
How Mycapssa works in the body
Octreotide binds to receptors in the blood vessels and causes them to constrict. This reduces the production of growth hormone, which is used to treat conditions caused by too much growth hormone. Octreotide also helps to reduce symptoms of tumors like carcinoid by reducing luteinizing hormone, splanchnic blood flow, and a range of hormones associated with digestion.
When to interrupt dosage
The suggested dosage of Mycapssa is contingent upon the diagnosed condition, including Acromegaly, Vasoactive Intestinal Peptide Tumors and metastatic Carcinoid Tumors. The measure of dosage shifts as indicated by the administration technique (e.g. Injection - Intravenous; Subcutaneous or Capsule, delayed release) featured in the table beneath.
Condition
Dosage
Administration
Flushing
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular
Carcinoid Tumor
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular
octreotide
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular
Acromegaly
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular
Gastroenteritis
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular
Vasoactive Intestinal Peptide Tumors
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular
long-term maintenance therapy
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular
Warnings
Mycapssa Contraindications
Condition
Risk Level
Notes
known hypersensitivity to the drug or any of the ingredients
Do Not Combine
There are 20 known major drug interactions with Mycapssa.
Common Mycapssa Drug Interactions
Drug Name
Risk Level
Description
Dotatate gallium Ga-68
Major
Octreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent.
Eliglustat
Major
The metabolism of Eliglustat can be decreased when combined with Octreotide.
Fentanyl
Major
The metabolism of Fentanyl can be decreased when combined with Octreotide.
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxyzine.
Lutetium Lu 177 dotatate
Major
The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.
Mycapssa Toxicity & Overdose Risk
There have been a few cases of octreotide overdose, which may cause low blood pressure, lack of oxygen to the brain, abnormal heart rhythm, heart stoppage, excess lactic acid in the body, inflammation of the pancreas, enlarged liver, diarrhea, redness in the face, fatigue, and weakness.
Mycapssa Novel Uses: Which Conditions Have a Clinical Trial Featuring Mycapssa?
41 active clinical trials are currently examining the potential of Mycapssa to provide metastatic Carcinoid Tumor, long-term maintenance therapy, and Flushing relief.
Condition
Clinical Trials
Trial Phases
Acromegaly
6 Actively Recruiting
Phase 2, Phase 3, Phase 1
Flushing
0 Actively Recruiting
Gastroenteritis
12 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1
Vasoactive Intestinal Peptide Tumors
0 Actively Recruiting
Carcinoid Tumor
1 Actively Recruiting
Early Phase 1
long-term maintenance therapy
0 Actively Recruiting
octreotide
0 Actively Recruiting
Patient Q&A Section about mycapssa
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there an oral form of octreotide?
"Octreotide is a drug that is available as an injection, and the new capsule formulation is taken orally."
Answered by AI
What is Mycapssa used for?
"Mycapssa (octreotide) is a oral medication used to treat acromegaly. It is a convenient option for those who have responded well to lanreotide or other forms of octreotide in the past."
Answered by AI